ACM
LKFT

Asymmetry Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Asymmetry Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6,250
Closed -$404K – 22
2016
Q3 		$404K Buy
+6,250
New +$352K 0.7% 18

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Asymmetry Capital Management's LKFT Position: Q4 2016 in Review

Asymmetry Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2016, closing a stake of 6,250 shares — an estimated $404K sold.

Asymmetry Capital Management first reported a position in LKFT in Q3 2016 and held it in 1 quarter. The position peaked at $404K in Q3 2016. 52 funds tracked by Wall St. Rank hold LKFT as of Q4 2016.

  • Asymmetry Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2016 after selling out during the quarter.
  • Asymmetry Capital Management sold 6,250 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2016, an estimated $404K.
  • Asymmetry Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and held it in 1 quarter.
  • Asymmetry Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $404K in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2016.

Based on Asymmetry Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.